Moreover, the anti-PD-1 monoclonal antibody nivolumab displayed a greater objective response rate and longer overall survival in patients with recurrent RCC compared to everolimus (Motzer et al., 2015; Alradhi et al., 2022). The gene discussed is PDCD1; the disease is renal cell carcinoma.